RT Journal Article
SR Electronic
T1 Adjuvant Recombinant SARS-CoV-2 Spike Protein Vaccine Immunogenicity After Prior mRNA Vaccine Doses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.07.24316865
DO 10.1101/2024.11.07.24316865
A1 Adelglass, Jeffrey M.
A1 Bradley, Paul
A1 Cai, Miranda R.
A1 Chau, Gordon
A1 Kalkeri, Raj
A1 Cloney-Clark, Shane
A1 Zhu, Mingzhu
A1 Cai, Zhaohui
A1 Eickhoff, Mark
A1 Plested, Joyce S.
A1 Mallory, Raburn M.
A1 Dunkle, Lisa M.
YR 2024
UL http://medrxiv.org/content/early/2024/11/08/2024.11.07.24316865.abstract
AB Background To support heterologous vaccine regimens, periodic SARS-CoV-2 revaccination required immunogenicity and safety data for adjuvanted protein-based vaccines following prior mRNA doses.Methods This phase 3, open-label study (2019nCoV-312/NCT05875701) enrolled participants who received one dose of ancestral SARS-CoV-2 protein-based vaccine (NVX-CoV2373) in an earlier study (2019nCoV-307/NCT05463068) after a primary series and possibly one additional dose of mRNA vaccine. In the current study, participants received an additional dose of protein-based vaccine (ancestral [n=104] or Omicron BA.5 [n=40]) at least 180 days after their previous study dose. The primary objective was demonstration of noninferiority of neutralizing antibody (nAb) titers induced by the dose in this study versus the first dose of NVX-CoV-2373 in the earlier study. Safety was also evaluated.Results A total of 144 participants were enrolled. The ratio of anti-Wuhan nAbs (GMT, IU/mL [95% CI]) at Day 28 after this study dose (ancestral 393.2 [318.0–468.2]) versus previous study dose (396.6 [328.7–478.6]) was 1.0 (0.8, 1.2), meeting noninferiority. The seroresponse rate difference between doses was 7.4% (95% CI = −1.2%–16.5%), also meeting noninferiority. Omicron BA.5 nAb titers suggest cross-protection against emerging variants. The nAb ratio at Day 28 between Omicron dose in this study (835.0 [597.1–1167.6]) versus previous study ancestral dose (436.0 [305.6–622.2]) was 1.9 (1.5–2.5), exceeding superiority criterion. Local and systemic reactions were similar between doses and strains in both studies.Conclusions A heterologous regimen of two adjuvanted recombinant spike protein-based vaccine doses after mRNA vaccination produced robust immune responses, exhibiting cross-reactivity to newer variants.Competing Interest StatementDisclosure of potential conflicts of interest: JMA and PB are investigators in the 2019nCoV-312 study. JMA is also an investigator in COVID vaccine studies with GSK, Moderna, Inc, Pfizer Inc, Medicago Inc, and CyanVac LLC. RC, GC, RK, SCC, MZ, ZC, ME, JSP, RMM, and LMD are current employees or consultants at Novavax, Inc and may hold stock in the company.Clinical TrialNCT05875701Funding StatementThis study was funded by Novavax, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Advarra, Inc. gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesStudy information is available online at links provided. Requests submitted to the corresponding author will be considered. https://www.clinicaltrials.gov/study/NCT05875701?term=2019nCoV-312&rank=1 https://www.clinicaltrials.gov/study/NCT05463068?term=NCT05463068&rank=1